HUP0200148A2 - Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention - Google Patents

Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention

Info

Publication number
HUP0200148A2
HUP0200148A2 HU0200148A HUP0200148A HUP0200148A2 HU P0200148 A2 HUP0200148 A2 HU P0200148A2 HU 0200148 A HU0200148 A HU 0200148A HU P0200148 A HUP0200148 A HU P0200148A HU P0200148 A2 HUP0200148 A2 HU P0200148A2
Authority
HU
Hungary
Prior art keywords
anthranilic acid
cinnamoyl
dimethoxy
prevention
reduction
Prior art date
Application number
HU0200148A
Other languages
Hungarian (hu)
Inventor
Jeffrey R. Granett
Neil H. Shusterman
David C. U'prichard
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of HUP0200148A2 publication Critical patent/HUP0200148A2/en
Publication of HUP0200148A3 publication Critical patent/HUP0200148A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A találmány az (I) képletű N-(3',4'-dimetoxi-cinnamoil)-antranilsavnak(N-5') vagy gyógyászatilag elfogadható sójának olyangyógyszerkészítmények előállítására történő alkalmazására vonatkozik,amely gyógyszerkészítmények emlősök, különösen emberek esetén végzettszívkoszorúér-műtéttel kapcsolatos cardiovascularis eseményekmegelőzésére vagy mérséklésére szolgálnak, ahol a szívkoszorúér-műtéthez kapcsolódóan körülbelül 300 mg és körülbelül 1100 mg közöttinapi dózist adnak be. ÓThe invention relates to the use of N-(3',4'-dimethoxycinnamoyl)-anthranilic acid (N-5') of the formula (I) or its pharmaceutically acceptable salt for the production of pharmaceutical preparations, which are pharmaceutical preparations for cardiovascular diseases associated with coronary artery surgery in mammals, especially humans are used to prevent or mitigate events where a daily dose of between about 300 mg and about 1100 mg is administered in association with coronary artery surgery. HE

HU0200148A 1999-02-03 2000-02-02 Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention HUP0200148A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11846399P 1999-02-03 1999-02-03

Publications (2)

Publication Number Publication Date
HUP0200148A2 true HUP0200148A2 (en) 2002-05-29
HUP0200148A3 HUP0200148A3 (en) 2003-06-30

Family

ID=22378760

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200148A HUP0200148A3 (en) 1999-02-03 2000-02-02 Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention

Country Status (17)

Country Link
EP (1) EP1180027A4 (en)
JP (1) JP2002536326A (en)
KR (1) KR20010101933A (en)
CN (1) CN1338930A (en)
AR (1) AR022475A1 (en)
AU (1) AU2978500A (en)
BR (1) BR0007901A (en)
CA (1) CA2361578A1 (en)
CO (1) CO5160246A1 (en)
HU (1) HUP0200148A3 (en)
IL (1) IL144719A0 (en)
MX (1) MXPA01007833A (en)
NO (1) NO20013789L (en)
PL (1) PL349926A1 (en)
TR (1) TR200102262T2 (en)
WO (1) WO2000045810A1 (en)
ZA (1) ZA200106297B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097650B2 (en) * 2005-07-27 2012-01-17 The Trustees Of Columbia University In The City Of New York Method of treating a condition associated with phosphorylation of TASK-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617407B2 (en) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 Preventive and therapeutic agent for intimal cell hyperproliferative disease
AU6837096A (en) * 1995-09-07 1997-03-27 Kissei Pharmaceutical Co. Ltd. 2-acylaminobenzamide derivatives and preventive and remedy for diseases caused by the supermultiplication of vascular intimal cells
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention

Also Published As

Publication number Publication date
KR20010101933A (en) 2001-11-15
EP1180027A1 (en) 2002-02-20
EP1180027A4 (en) 2004-11-17
CA2361578A1 (en) 2000-08-10
AU2978500A (en) 2000-08-25
MXPA01007833A (en) 2002-06-21
BR0007901A (en) 2001-10-30
CO5160246A1 (en) 2002-05-30
NO20013789L (en) 2001-09-28
AR022475A1 (en) 2002-09-04
NO20013789D0 (en) 2001-08-02
PL349926A1 (en) 2002-10-21
ZA200106297B (en) 2002-07-31
JP2002536326A (en) 2002-10-29
HUP0200148A3 (en) 2003-06-30
TR200102262T2 (en) 2002-02-21
WO2000045810A1 (en) 2000-08-10
IL144719A0 (en) 2002-06-30
CN1338930A (en) 2002-03-06

Similar Documents

Publication Publication Date Title
CA2106172A1 (en) Use of 2-(3,4-Dimethoxycinnamoyl)Aminobenzoic Acid for the Treatment of Restenosis Associated with Coronary Intervention
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
CA2179521A1 (en) 2,4-disulphophenyl butylnitrone, its salts and their use as pharmaceuti cal spintraps
DK1623703T3 (en) Controlled release hydrocodone formulations
NO922004L (en) ORAL PREPARATION FOR TREATMENT OF INFLAMMATORY GAS DISORDERS
HK1087336A1 (en) Pharmaceutical composition comprising lumiracoxib
DE69731610D1 (en) ORAL ADMINISTRATION OF EFFECTIVE AMOUNTS OF HYALURONIC ACID
NO307495B1 (en) Use of riluzole in the manufacture of medications for the treatment of Parkinson's disease and Parkinson's syndromes
HUP0102365A2 (en) Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant and process for their preparation
BR9709838A (en) Administration regimen that provides a blood plasma profile of an h +, k + -atpase inhibitor oral pharmaceutical composition and the use of h +, k + -atpase inhibitor and processes to improve the inhibition of gastric acid secretion and the therapeutic effect on treatment of gastrointestinal disorders and to receive an extended plasma profile of an h +, k + -atpase inhibitor
BG105173A (en) Novel salt form of pantoprazole
HUP0202671A2 (en) Optically active isomers of ketotifen and therapeutically active metabolites thereof
HUP0302068A2 (en) Use of cox-2 inhibitors for treating or preventing immunodeficiency and pharmaceutical compositions containing them
EP0375628A3 (en) Use of acetyl l-carnitine in the therapeutic treatment of cataract, and pharmaceutical compositions useful in such treatment
HUP0203716A2 (en) Substituted n-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect and pharmaceutical compositions containing them
KR970061244A (en) Pharmaceutical composition for treating dementia
JP2005511619A5 (en)
CA2003856A1 (en) Therapeutic agent for renal disorders
HUP9901659A2 (en) Use of flupirtin for producing pharmaceutical compositions suitable for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system
HUP0200148A2 (en) Use of n-(3',4'-dimethoxy-cinnamoyl)-anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention
HUP0401798A2 (en) Use of rosuvastatin for preparation of pharmaceutical compositions usable in pre demented states
HUP0402062A2 (en) Use of alkanoyl l-carnitine for the treatment of erectile dysfunction and pharmaceutical compositions containing them
ATE91890T1 (en) MANUFACTURE OF A DRUG AGAINST ARTHRITIS AND RHEUMATISM.
HUP0200129A2 (en) Use of n-(3'4'-dimethoxycinnamoyl) anthranilic acid for the prevention or reduction of cardiovascular events associated with coronary intervention
HUP0002941A2 (en) Glutathione reductase activity potentiator containing troglitazone